OTCMKTS:RCDTF Recordati Industria Chimica e Farmaceutica (RCDTF) Stock Price, News & Analysis $52.25 0.00 (0.00%) (As of 11/21/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartEarningsHeadlinesShort Interest About Recordati Industria Chimica e Farmaceutica Stock (OTCMKTS:RCDTF) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get RCDTF alerts:Sign Up Key Stats Today's Range$52.25▼$52.2550-Day Range$52.25▼$52.2552-Week Range$52.25▼$52.25VolumeN/AAverage Volume2 shsMarket CapitalizationN/AP/E Ratio26.13Dividend YieldN/APrice TargetN/AConsensus RatingReduce Company OverviewRecordati Industria Chimica e Farmaceutica S.p.A., together with its subsidiaries, engages in the research, development, manufacture, and marketing of pharmaceuticals worldwide. The company operates through Specialty and Primary Care and Rare Diseases segments. Its product pipeline includes REC 0559 which is in Phase II for the treatment of Neurotrophic Keratitis; REC 0545 for acute decompensation in maple syrup urine diseases; ISTURISA for endogenous Cushing's syndrome; and CYSTADROPS, an corneal cystine deposits in patients with cystinosis. The company also develops CARBAGLU for hyperammonemia due to NAGS deficiency; QARZIBA, an apeiron for the treatment of high-risk neuroblastoma patients with a partial response at the chemotherapeutical through myeloablative therapy and stem cell transplantation, and relapsed or refractory neuroblastoma. In addition, it offers SYLVANT for the treatment of idiopathic multicentric Castleman diseases; REAGILA for Schizophrenia; and ELIGARD for hormone-dependent prostate cancer, as well as CAPHOSOL, a medical device for treatment of oral mucositis due to chemo and radiation therapy. The company was founded in 1926 and is headquartered in Milan, Italy. Recordati Industria Chimica e Farmaceutica S.p.A. operates as a subsidiary of Rossini S.à R.L.Read More… Trump’s IRS Hands Massive ‘Victory Gift’ To 401K Owners (Ad)Trump quietly left open an "off the books" wealth-protection loophole hidden in the 6,871 pages of the IRS Tax Code… And since then… "In the know" patriots have quietly used this same "Trump revenge loophole" to shield their life savings from Bidenomics…Get Your Free Gold Guide Receive RCDTF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Recordati Industria Chimica e Farmaceutica and its competitors with MarketBeat's FREE daily newsletter. Email Address RCDTF Stock News HeadlinesRecordati’s Strategic Share Buyback InitiativeNovember 21 at 3:18 AM | markets.businessinsider.comRecordati Completes Share Buy-Back ProgramNovember 12, 2024 | markets.businessinsider.comWhat This Post-Election Shift Means for Your InvestmentsThe election may be over, but its impact on financial markets is only beginning. New trends are emerging, bringing both challenges and opportunities for investors. Many of these changes are flying under the radar, yet they have the potential to reshape the financial landscape for years to come. Understanding how these shifts could affect your wealth—and what steps to take—has never been more important.November 22, 2024 | InvestorPlace (Ad)Recordati Launches Share Buy-Back Program to Boost IncentivesNovember 12, 2024 | markets.businessinsider.comItaly's Recordati sees no impact from potential US pharma tariffsNovember 9, 2024 | msn.comRecordati Enhances Share Value with Buyback ProgramNovember 7, 2024 | markets.businessinsider.comRBC Capital Reaffirms Their Hold Rating on Recordati Industria Chimica e Farmaceutica SPA (0KBS)November 6, 2024 | markets.businessinsider.comRecordati Advances in Share Buyback ProgramOctober 30, 2024 | markets.businessinsider.comSee More Headlines RCDTF Stock Analysis - Frequently Asked Questions How have RCDTF shares performed this year? Recordati Industria Chimica e Farmaceutica's stock was trading at $46.00 on January 1st, 2024. Since then, RCDTF shares have increased by 13.6% and is now trading at $52.25. View the best growth stocks for 2024 here. How do I buy shares of Recordati Industria Chimica e Farmaceutica? Shares of RCDTF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. Company Calendar Today11/22/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Private households Sub-IndustryN/A Current SymbolOTCMKTS:RCDTF Previous SymbolNASDAQ:RCDTF CUSIPN/A CIKN/A Webwww.recordati.com Phone390-248-7871Fax39-02-4007-3747Employees4,455Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)$2.00 Trailing P/E Ratio26.13 Forward P/E RatioN/A P/E GrowthN/ANet Income$421.25 million Net Margins17.41% Pretax MarginN/A Return on Equity30.78% Return on Assets12.65% Debt Debt-to-Equity Ratio0.73 Current Ratio1.36 Quick Ratio0.95 Sales & Book Value Annual Sales$2.25 billion Price / SalesN/A Cash Flow$3.06 per share Price / Cash Flow17.08 Book Value$7.90 per share Price / Book6.61Miscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable Beta0.34 These 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free Report This page (OTCMKTS:RCDTF) was last updated on 11/22/2024 by MarketBeat.com Staff From Our Partners[Urgent] Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it a...Paradigm Press | Sponsored[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you k...Crypto Swap Profits | SponsoredThe Biggest Post-Election Market Shift Ever?Our No. 1 stock for the rare "millionaire window" opening NOW According to Wall Street legend Whitney Tilso...Stansberry Research | SponsoredMy favorite credit card just increased its sign-up bonusTired of getting average credit card rewards? This credit card just increased its sign-up bonus to 75,000 bonu...Card Ratings | SponsoredBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredWhy Buffett, Bezos & Congress Are Rushing Into This SectorWhy are Warren Buffett, Jeff Bezos, Michael Bloomberg, “The Walmart Family”, Bill Gates, and 48 members of Con...InvestorPlace | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Recordati Industria Chimica e Farmaceutica S.p.A. Please log in to your account or sign up in order to add this asset to your watchlist. Share Recordati Industria Chimica e Farmaceutica With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.